Jpmorgan Chase & CO Vaccitech PLC Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Shares
2 transactions
Others Institutions Holding VACC
# of Institutions
20Shares Held
14.9MCall Options Held
0Put Options Held
0-
M&G PLC London, X05.2MShares$17.7 Million0.02% of portfolio
-
M&G Investment Management LTD London, X05.2MShares$17.7 Million0.07% of portfolio
-
Alphabet Inc. Mountain View, CA1.51MShares$5.16 Million0.35% of portfolio
-
Sc China Holding LTD N/A, K31.42MShares$4.84 Million0.18% of portfolio
-
Dc Funds, LP Mclean, VA642KShares$2.19 Million33.3% of portfolio
About Vaccitech plc
- Ticker VACC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,216,200
- Market Cap $127M
- Description
- Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B...